Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas corticosteroids have effective results. Corticosteroids need to be carefully administered, to avoid adverse effects, mainly the secondary development of glaucoma, cataracts, or infections. Immunosuppressive agents, such as cyclosporin (CyA) or tacrolimus are, therefore, frequently employed in VKC patients. Only the 0.1% CyA (1 mg/mL) concentration has an approved and specific clinical indication for the treatment of VKC and this drug was given the denomination of orphan drug by the European Commission (EU/3/06/360) in 2006. So far, few studies have been conducted to evaluate the efficacy and the side effects of topical 0.1% CyA. Different topical CyA concentrations, ranging from 0.05% to 2%, and various types of formulation are available at the moment. In the future, 0.1% CyA will presumably take an important part in the management of VKC. The present review focuses on eye drops containing 0.1% CyA; however, more studies will be needed to define its long-term efficacy in the natural course of this severe ocular disease.

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy / Nebbioso, Marcella; Alisi, Ludovico; Giovannetti, Francesca; Armentano, Marta; Lambiase, Alessandro. - In: CLINICAL OPHTHALMOLOGY. - ISSN 1177-5483. - 13:(2019), pp. 1147-1155. [10.2147/OPTH.S181811]

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy

Nebbioso, Marcella
Primo
Writing – Review & Editing
;
Alisi, Ludovico
Secondo
Writing – Original Draft Preparation
;
Giovannetti, Francesca
Data Curation
;
Armentano, Marta
Penultimo
Software
;
Lambiase, Alessandro
Ultimo
Project Administration
2019

Abstract

Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas corticosteroids have effective results. Corticosteroids need to be carefully administered, to avoid adverse effects, mainly the secondary development of glaucoma, cataracts, or infections. Immunosuppressive agents, such as cyclosporin (CyA) or tacrolimus are, therefore, frequently employed in VKC patients. Only the 0.1% CyA (1 mg/mL) concentration has an approved and specific clinical indication for the treatment of VKC and this drug was given the denomination of orphan drug by the European Commission (EU/3/06/360) in 2006. So far, few studies have been conducted to evaluate the efficacy and the side effects of topical 0.1% CyA. Different topical CyA concentrations, ranging from 0.05% to 2%, and various types of formulation are available at the moment. In the future, 0.1% CyA will presumably take an important part in the management of VKC. The present review focuses on eye drops containing 0.1% CyA; however, more studies will be needed to define its long-term efficacy in the natural course of this severe ocular disease.
atopy; conjunctivitis; cyclosporin; keratitis; ocular inflammation; vernal keratoconjunctivitis
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy / Nebbioso, Marcella; Alisi, Ludovico; Giovannetti, Francesca; Armentano, Marta; Lambiase, Alessandro. - In: CLINICAL OPHTHALMOLOGY. - ISSN 1177-5483. - 13:(2019), pp. 1147-1155. [10.2147/OPTH.S181811]
File allegati a questo prodotto
File Dimensione Formato  
Nebbioso_Eye drop emulsion_2019.pdf

accesso aperto

Note: https://www.dovepress.com/eye-drop-emulsion-containing-01-cyclosporin-1-mgml-for-the-treatment-o-peer-reviewed-article-OPTH
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.78 MB
Formato Adobe PDF
1.78 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1301605
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact